Merger and acquisitions may be a path to creating value for life science companies, but talks can breakdown because of flaws in management thinking that skew their sense of the value of their company. Oded Ben-Joseph, managing director of Outcome Capital, applied behavioral economics to the M&A front to discuss how cognitive biases can derail M&A transactions…
The Bio Report
Merger and acquisitions may be a path to creating value for life science companies, but talks can breakdown because of flaws in management thinking that skew their sense of the value of their company. Oded Ben-Joseph, managing director of Outcome Capital, applied behavioral economics to the M&A front to discuss how cognitive biases can derail M&A transactions in an article in the September issue of In Vivo. We spoke to Ben-Joseph about cognitive biases, why the life sciences sector is particularly prone to the problem, and what executives can do to minimize their effects.
Outcome Capital has won honors as the Top Life Sciences Advisory & Investment Banking Firm – 2024 per Life Sciences Magazine January 2024 Read the full article from Life Science Magazine here: Read More
Read MoreOutcome Capital Life Science Market Pulse March 2024 Click to view our LifeSciences Pulse Newsletter
DownloadWould you like to learn more about working with Outcome Capital or discuss your specific needs?